Note: If you use other eye drops in addition to Restasis, you can probably still use those drops while you’re using Restasis. But make sure to check with your doctor about which eye drops are safe to ...

Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful ...

Allergan is spiking up $2.31, or 4.4 percent, to $55.05 after the company said the U.S. Food and Drug Administration had approved Restasis use in patients suffering from chronic dry eye disease. The ...

Please provide your email address to receive an email when new articles are posted on . Allergan announced it has received FDA approval for Restasis Multidose, a preservative-free, multidose bottle ...

Yes, people with Medicare Part D who use Restasis may be eligible for a patient assistance program called myAbbVie Assist. This article discusses whether Medicare covers Restasis, Medicare ...

Sight Sciences Inc SGHT released the six-month SAHARA randomized controlled trial comparing interventional eyelid procedures enabled by TearCare Technology to Restasis for dry eye disease. TearCare is ...

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a new challenge named Xiidra lies ahead.

Please provide your email address to receive an email when new articles are posted on . They said it would never happen. We would never see it in our lifetimes. It was a dream held by millions, but ...

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing ...